The Industry

April 2007
Pharmaceutical Representative;Apr2007, Vol. 37 Issue 4, p10
The article provides updates in the pharmaceutical industry in the U.S. Wyeth Pharmaceuticals in Collegeville, Pennsylvania has launched several joint ventures, including with Marrieta, Leuven, and Evry. A conditional marketing approval has been received by Tibotec Pharmaceuticals Ltd. from the European Commission for its protease inhibitor Prezista. Jazz Pharmaceuticals Inc. signed a product license agreement with Solvay Pharmaceuticals Inc. to market certain drugs in the U.S.


Related Articles

  • Jazz Pharma Prices IPO: Nabs $108M For Luvox.  // Bioworld Week;6/11/2007, Vol. 15 Issue 24, p2 

    The article announces the initial public offering (IPO) of Jazz Pharmaceuticals Inc. The company is selling 6 million shares at $18 each. The proceeds of the sale will be used to launch an approvable Luvox CR for psychiatric disorders. Jazz Pharmaceuticals will focus on pushing to market Luvox...

  • The Industry.  // Pharmaceutical Representative;Jan2009, Vol. 39 Issue 1, p10 

    The article offers global news briefs related to pharmaceutical industry. Jazz Pharmaceuticals Inc. has reduced its sales force through eliminating 67 jobs due to the disappointing sales of its social anxiety disorder and obsessive-compulsive disorder drug. Alpharma Inc. has acquired by King...

  • OTHER NEWS TO NOTE.  // BioWorld Today;8/6/2007, Vol. 18 Issue 151, p2 

    The article offers news briefs on the pharmaceutical industry. Gene Network Sciences Inc. entered an agreement with CombinatoRx Inc. to contribute to ongoing mechanism of action research. Jazz Pharmaceuticals Inc. said the FDA has accepted for review the submission of the complete response by...

  • R&D Update.  // PharmaWatch: CNS;Jul2008, Vol. 7 Issue 7, p14 

    The article offers news briefs related to pharmaceutical research and development (R&D). Wyeth Pharmaceuticals and Progenics Pharmaceuticals Inc. released results of two clinical trials regarding oral and intravenous formulations of Relistor. Avanir Pharmaceuticals revealed positive results on...

  • TIBOTEC GETS AIDS. Armstrong, Walter // Pharmaceutical Executive;Aug2007, Vol. 27 Issue 8, p48 

    The article offers information about Tibotec, a biotech born in Belgium in 1994 and was bought by Johnson & Johnson in 2002 for $320 million. The company is responsible for the releases of drugs Prezista, a protease inhibitor, and etravarine and rilpivirine, two new non-nucleosides. Its latest...

  • TIBOTEC UNVEILS U.S. EXPANDED ACCESS PROGRAM FOR TMC114.  // Worldwide Biotech;Dec2005, Vol. 17 Issue 12, p6 

    Reports on the launching of the expanded access program of Tibotec Pharmaceuticals Ltd. for its investigational protease inhibitor TMC114, in the U.S. Information on TMC114; Overview of the expanded access program; Background of the company.

  • Solvay and Wyeth: potential blockbuster submitted for approval.  // PharmaWatch: CNS;Nov2006, Vol. 5 Issue 11, p11 

    The article reports that an application has been filed by Solvay Pharmaceuticals Inc. and Wyeth Pharmaceuticals to the U.S. Food and Drug Administration. The application refers to a new schizophrenia treatment by the use of bifeprunox. To check its safety and efficacy, antipsychotic bifeprunox...

  • Medivir, Tibotec Expand HCV Work in Potential $430M Deal. Boggs, Jennifer // BioWorld Today;5/20/2008, Vol. 19 Issue 98, p1 

    The article reports on the plan of biotechnology firms Medivir AB and Tibotec BVBA to develop a drug for the treatment of hepatitis C which is caused by viral infection. The deal will worth 277 million euro where Tibotec will have global marketing rights except in the Nordic countries. Lars...

  • Solvay Develops Mammalian-Cell Influenza Vaccine. Scott, Alex // Chemical Week;2/12/2003, Vol. 165 Issue 6, p18 

    Discusses the plan of Solvay Pharmaceuticals to manufacture influenza vaccines based on a novel mammalian cell line, as of February 12, 2003. Budget allocation for the project; Details of the production method; Advantages of the planned facility.


Read the Article


Sign out of this library

Other Topics